scholarly journals Test trial of spike‐in immunoglobulin heavy‐chain ( IGH ) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia

2020 ◽  
Vol 189 (4) ◽  
Author(s):  
Guilherme Navarro Nilo Giusti ◽  
Patrícia Yoshioka Jotta ◽  
Caroline de Oliveira Lopes ◽  
Monica Aparecida Ganazza ◽  
Amilcar Cardoso Azevedo ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Acute Lymphoblastic Leukaemia ◽  
Test Trial ◽  
Minimal Residual Disease ◽  
Heavy Chain ◽  
Lymphoblastic Leukaemia ◽  
Residual Disease ◽  
Next Generation ◽  
Generation Sequencing ◽  
Minimal Residual

scholarly journals Monitoring of minimal residual disease in early T‐cell precursor acute lymphoblastic leukaemia by next‐generation sequencing

2016 ◽  
Vol 176 (2) ◽  
pp. 318-321 ◽  
Author(s):  
Xiaoqing Pan ◽  
Naoki Nariai ◽  
Noriko Fukuhara ◽  
Sakae Saito ◽  
Yukuto Sato ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
T Cell ◽  
Acute Lymphoblastic Leukaemia ◽  
Minimal Residual Disease ◽  
Lymphoblastic Leukaemia ◽  
Residual Disease ◽  
Next Generation ◽  
Cell Precursor ◽  
Generation Sequencing ◽  
Minimal Residual

scholarly journals Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia

2016 ◽  
Vol 176 (2) ◽  
pp. 248-257 ◽  
Author(s):  
Yuko Sekiya ◽  
Yinyan Xu ◽  
Hideki Muramatsu ◽  
Yusuke Okuno ◽  
Atsushi Narita ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Acute Lymphoblastic Leukaemia ◽  
B Cell ◽  
Minimal Residual Disease ◽  
Lymphoblastic Leukaemia ◽  
Clinical Utility ◽  
Residual Disease ◽  
Next Generation ◽  
Generation Sequencing ◽  
Minimal Residual

scholarly journals Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

2020 ◽  
Vol 22 (5) ◽  
pp. 679-684 ◽  
Author(s):  
Qiumei Yao ◽  
Yinlei Bai ◽  
Alberto Orfao ◽  
Shaji Kumar ◽  
Chor S. Chim
Keyword(s):  
Multiple Myeloma ◽  
Next Generation Sequencing ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Disease Detection ◽  
Next Generation ◽  
Minimal Residual Disease Detection ◽  
Generation Sequencing ◽  
Minimal Residual

scholarly journals Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

2020 ◽  
Author(s):  
Caleb Ho ◽  
Mustafa Syed ◽  
Mikhail Roshal ◽  
Kseniya Petrova-Drus ◽  
Christine Moung ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Next Generation ◽  
Generation Sequencing ◽  
Minimal Residual

scholarly journals Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms

2020 ◽  
Vol 9 (12) ◽  
pp. 3818
Author(s):  
Paula Aguirre-Ruiz ◽  
Beñat Ariceta ◽  
María Cruz Viguria ◽  
María Teresa Zudaire ◽  
Zuriñe Blasco-Iturri ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Minimal Residual Disease ◽  
Peripheral Blood ◽  
Residual Disease ◽  
Mixed Chimerism ◽  
Clinical Relapse ◽  
Next Generation ◽  
Myeloid Neoplasms ◽  
Generation Sequencing ◽  
Minimal Residual

Patients with myeloid neoplasms who relapsed after allogenic hematopoietic stem cell transplant (HSCT) have poor prognosis. Monitoring of chimerism and specific molecular markers as a surrogate measure of relapse is not always helpful; therefore, improved systems to detect early relapse are needed. We hypothesized that the use of next generation sequencing (NGS) could be a suitable approach for personalized follow-up post-HSCT. To validate our hypothesis, we analyzed by NGS, a retrospective set of peripheral blood (PB) DNA samples previously evaluated by high-sensitive quantitative PCR analysis using insertion/deletion polymorphisms (indel-qPCR) chimerism engraftment. Post-HCST allelic burdens assessed by NGS and chimerism status showed a similar time-course pattern. At time of clinical relapse in 8/12 patients, we detected positive NGS-based minimal residual disease (NGS-MRD). Importantly, in 6/8 patients, we were able to detect NGS-MRD at time points collected prior to clinical relapse. We also confirmed the disappearance of post-HCST allelic burden in non-relapsed patients, indicating true clinical specificity. This study highlights the clinical utility of NGS-based post-HCST monitoring in myeloid neoplasia as a complementary specific analysis to high-sensitive engraftment testing. Overall, NGS-MRD testing in PB is widely applicable for the evaluation of patients following HSCT and highly valuable to personalized early treatment intervention when mixed chimerism is detected.

Sign in / Sign up

Export Citation Format

Share Document